Antinociceptive effect of natural and synthetic alkamides involves TRPV1 receptors

Journal of Pharmacy and Pharmacology

Volumn 69, Issue 7, 2017, Pages 884-895

  de la Rosa Lugo, Vianey ^a   Acevedo Quiroz, Macdiel ^a   Déciga Campos, Myrna ^b   Rios, María Yolanda ^a  

^a CENTRO DE INVESTIGACIONES QUÍMICAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

affinin; alkamides; antinociception; capsaicin; Heliopsis longipes

Indexed keywords

AFFININ; AMIDE; CAPSAICIN; CAPSAZEPINE; DIAZEPAM; LONGIPINAMIDE A; LONGIPINAMIDE B; N ISOBUTYL DIHYDROFERULOYLAMIDE; N ISOBUTYL FERULOYLAMIDE; NATURAL PRODUCT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ANALGESIC AGENT; TRPV1 RECEPTOR; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; FACE; FEMALE; FORMALIN TEST; HELIOPSIS LONGIPES; MOUSE; MOUTH; NONHUMAN; PLANT ROOT; SEIZURE; ANALOGS AND DERIVATIVES; ANIMAL; ASTERACEAE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; FACE PAIN; METABOLISM; PAIN MEASUREMENT;

AMIDES; ANALGESICS; ANIMALS; ASTERACEAE; CAPSAICIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FACIAL PAIN; FEMALE; MICE; PAIN MEASUREMENT; TRPV CATION CHANNELS;

EID: 85017363976     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12721     Document Type: Article

References (31)

1. Rios MY, Olivo HF. Chapter 3 – Natural and synthetic alkamides: applications in pain therapy. In Studies in Natural Products Chemistry. Ed. Atta-ur-Rahman. 2014; 43: 79.
2. Nagy I et al. Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. Prog Drug Res 2014; 68: 39–76.
3. Por ED et al. β-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 2012; 287: 37552–37563.
4. Rios MY et al. Analgesic activity of affinin, an alkamide from Heliopsis longipes (Compositae). J Ethnopharmacol 2007; 110: 364–367.
5. Arriaga-Alba M et al. Antimutagenic properties of affinin isolated from Heliopsis Longipes extract. Pharm Biol 2013; 51: 1035–1039.
6. Déciga-Campos M et al. Pharmacological and toxicological profile of extract from Heliopsis longipes and affinin. Drug Dev Res 2012; 137: 130–137.
7. Déciga-Campos M et al. Antinociceptive effect of Heliopsis longipes extract and affinin in mice. Planta Med 2010; 76: 665–670.
8. Ueda H. In vivo molecular signal transduction of peripheral mechanisms of pain. Jpn J Pharmacol 1999; 79: 263–268.
9. Raboisson P. The orofacial formalin test. Neurosci Biobehav Rev 2004; 28: 219–226.
10. Schiffman E et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the international RDC/TMD consortium network and orofacial pain special interest group. J Oral Facial Pain Headache 2014; 28: 6–27.
11. Van der Stelt M, Di Marzo V. Endovanilloids. Eur J Biochem 2004; 271: 1827–1834.
12. Gerhold KA, Bautista DM. Molecular and cellular mechanisms of trigeminal chemosensation. Ann N Y Acad Sci 2009; 1170: 184–189.
13. Cavanaugh DJ et al. Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J Neurosci 2011; 31: 5067–5077.
14. Gannett PM et al. Capsaicinoids: their separation, synthesis, and mutagenicity. J Org Chem 1988; 53: 1064–1071.
15. López-Martínez S et al. Minor alkamides from Heliopsis longipes S.F Blake (Asteraceae) fresh roots. Phytochem Lett 2011; 4: 275–279.
16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109–110.
17. Gao Y et al. TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nature 2016; 534: 347–351.
18. Zheng J, Ma L. Structure and function of the thermoTRP channel pore. Curr Top Membr 2014; 74: 233–257.
19. Yang F et al. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nat Chem Biol 2015; 11: 518–524.
20. Cao E et al. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 2013; 504: 113–118.
21. Walpole CS et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain “C-region”. J Med Chem 1993; 36: 2381–2389.
22. Matsuura S et al. Mechanisms underlying ectopic persistent tooth-pulp pain following pulpal inflammation. PLoS One 2013; 8: e52840.
23. Cruz LS et al. Intraganglionar resiniferatoxin prevents orofacial inflammatory and neuropathic hyperalgesia. Behav Pharmacol 2014; 25: 112–118.
24. Caterina MJ. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816–824.
25. Papoiu ADP, Yosipovitch G. Topical capsaicin. The fire of a “hot” medicine is reignited. Expert Opin Pharmacother 2010; 11: 1359–1371.
26. Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol 2001; 14: 187–192.
27. Kong W-L et al. Role of TRPV1 in susceptibility to PTZ-induced seizure following repeated hyperthermia challenges in neonatal mice. Epilepsy Behav 2014; 31: 276–280.
28. Clinckers R et al. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett 2005; 390: 48–53.
29. Gonzalez-Reyes LE et al. TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo. Exp Neurol 2013; 250: 321–332.
30. Messeguer A et al. Physiology and pharmacology of the vanilloid receptor. Curr Neuropharmacol 2006; 4: 1–15.
31. Nazıroğlu M. TRPV1 channel: a potential drug target for treating epilepsy. Curr Neuropharmacol 2015; 13: 239–247.